Details for Patent: 8,604,020

Which drugs does patent 8,604,020 protect, and when does it expire?

Patent 8,604,020 protects BESIVANCE and is included in one NDA.

This patent has eleven patent family members in ten countries.

Summary for Patent: 8,604,020

Title:	Fluoroquinolone carboxylic acid molecular crystals
Abstract:	Disclosed herein is a molecular crystal form of (R)-(+)-7-(3-amino-2,3,4,5,6,7-hexahydro-1H-azepin-1-yl)-1-cyclopropyl-8-chloro-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid. The molecular crystal is characterized by at least one of: (a) an X-ray powder diffraction (“XRPD”) spectrum that comprises peaks at 2θ angles of 10.6, 15, 19.7, 21.1, and 22°±0.2°; (b) a DSC melting peak at 288° C.; (c) a 13C NMR spectrum having peaks at 23.3, 27.7, 41.1, 54.5, 116.6, and 153.5 ppm; and (d) pKa values of 5.65 and 9.91. The compound belongs to the class of fluoroquinolones and is useful as an antibacterial agent.
Inventor(s):	Harry M. King, JR.
Assignee:	Bausch and Lomb Inc
Application Number:	US13/826,469
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,604,020
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 8,604,020

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bausch And Lomb	BESIVANCE	besifloxacin hydrochloride	SUSPENSION/DROPS;OPHTHALMIC	022308-001	May 28, 2009		RX	Yes	Yes	8,604,020		Y

International Family Members for US Patent 8,604,020

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	075926
Brazil	PI1009849
Canada	2756769
China	102369189